A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. - Wikidata - wikimedia - TriplyDB

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

http://www.wikidata.org/entity/Q41045405

about

Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis A unified model of the hierarchical and stochastic theories of gastric cancer.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Immunotherapy for gastric cancers: emerging role and future perspectives.Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.Novel Targeted Therapies for Esophagogastric Cancer.Underlying Mechanisms for Distant Metastasis - Molecular Biology.The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis.Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Targeting MET in cancer therapy.New therapeutic options opened by the molecular classification of gastric cancer.Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?

P2860

Q33441654-2D439835-E4D4-4E98-A8D2-E9D037A93D6D Q33577624-8D7B61CE-80D3-48EC-9EDC-A801B8DB82EC Q36307708-B69347C9-9F6F-4638-8C0F-37D00EBA2B20 Q38602669-517C1B17-8C84-44E6-9522-D3DF81D552B3 Q38684349-EE1395D6-C197-4F8B-880D-00644BEA1B34 Q38738652-35312C3E-C581-4D8D-8554-CDACF26B33B3 Q39038994-E2C09B1E-8DFF-4D46-8B67-D6766DE306A1 Q39171565-13C0F77C-1616-4B54-A068-257AF31BCA4F Q40102636-FB1358A1-CDCA-4915-AED9-C29D0095EEEC Q42265610-2CE230A0-1358-46D9-A376-31811852BC78 Q42693879-83A39D35-0A26-4D7B-9B92-D87D26E185A5 Q47402625-E7EA8C08-22ED-427C-85BC-A6BBAAFD4568 Q54987450-AF923402-9DC6-4A2A-870E-7C53D89336EF Q55527185-2AAD820C-05AA-46E7-8D2C-25DA3FF17D1C Q58555802-56081CC8-8D37-4153-9528-342E645D9292

P2860

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

http://www.wikidata.org/entity/Q41045405

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A Randomized Phase II Study of ...... and Gastroesophageal Junction.

@en

type

label

A Randomized Phase II Study of ...... and Gastroesophageal Junction.

@en

prefLabel

A Randomized Phase II Study of ...... and Gastroesophageal Junction.

@en

P1433

Q41045405-92042618-1DD1-45D2-A8B7-E1DC3756A6E7

P1476

Q41045405-36FFA603-B43A-4008-B805-3144128E7359

P2093

Q41045405-2723B2AA-6269-4E19-A499-D888C2F60396

Q41045405-40D8D16E-9ED7-4628-9ADB-467C3B60D479

Q41045405-4458EC79-4A0C-4766-AD61-A4137FD2F747

Q41045405-48E66549-EFC6-4921-A205-71E35931E37C

Q41045405-5A2B296E-F35E-45E2-982B-2565679E4B2D

Q41045405-60087474-C506-49EF-A4BE-60BC3F6C9207

Q41045405-A73B9635-26E8-487C-9F85-088C424189B7

Q41045405-B4260419-E563-40BE-AA9F-5E5A3D34FD6E

P2860

Q41045405-25084555-0F05-4FA0-94AC-033801EB8260

Q41045405-287CFDF9-20A0-453B-98CA-9A94FF19999C

Q41045405-6253D88B-8627-4BF9-8703-7C5E009DF98C

Q41045405-89A5B186-55F2-4499-A0B4-91CE197ED77E

Q41045405-8CEC63C0-1EAA-4A06-B355-274EC90DF0EA

Q41045405-9711A800-48A8-4E72-9C57-609CB1D2C4D9

Q41045405-A0258E75-CE63-4A9C-BE4C-F718AA477933

Q41045405-A449ECDF-D098-40DA-B174-1EC959D0689E

Q41045405-A47FDE35-BE80-4F05-AF84-67F3001DA82F

Q41045405-BE20C541-6018-4196-9FCB-97FABA72FBF7

P304

Q41045405-6A22A105-5E08-42A8-AD78-CF155482363F

P31

Q41045405-0156CE0B-4FEA-4465-8C1D-0EE9C86F1AEF

P356

Q41045405-991B1556-6E0D-46C2-9B7D-E60F0813E6A1

P433

Q41045405-A296E0C4-665C-426E-963B-85CDE29030DC

P478

Q41045405-95289E5B-140F-4877-9F7C-520ED26F1594

P50

Q41045405-3CA36A52-6279-4F97-AD90-AA6D5BED2B7C

P577

Q41045405-EF582FD6-382B-4FC5-8FC3-8C30637AD67C

P698

Q41045405-303D8705-F768-448E-8B35-597A6AE5A852

P932

Q41045405-D6701599-A12C-438A-9CF4-7F2EDE812085

P356

THEONCOLOGIST.2016-0038

P1433

P1476

A Randomized Phase II Study of ...... and Gastroesophageal Junction

@en

P2093

Alice Kang

http://www.w3.org/2001/XMLSchema#string

Chia-Jui Yen

http://www.w3.org/2001/XMLSchema#string

David S Shames

http://www.w3.org/2001/XMLSchema#string

Iain B Tan

http://www.w3.org/2001/XMLSchema#string

Lilian Bu

http://www.w3.org/2001/XMLSchema#string

Manish A Shah

http://www.w3.org/2001/XMLSchema#string

Niall C Tebbutt

http://www.w3.org/2001/XMLSchema#string

Yoon-Koo Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Update on metastatic gastric and esophageal cancers.

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

P304

1085-1090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2016-0038

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27401892

http://www.w3.org/2001/XMLSchema#string

P932

5016069

http://www.w3.org/2001/XMLSchema#string